

CIN No:- L24230PB2006PLC030341  
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/21-22/BSE-11

Date 30/06/2021

To

Department of Corporate Services,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001

**Ref: BSE Security Code 540694**

**Sub: Audited Financial Results For the Half Year and Financial Year ended 31<sup>st</sup> March, 2021**

Dear Sir/ Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith:

1. Audited Financial Results of the Company for the half year and financial year ended March 31, 2021 as approved in the Board of Directors Meeting held today, along with the Auditor's Report thereon received from M/s Raman Wadhwa & Co., Statutory Auditors of the Company.
2. Declaration pursuant to Reg. 33(3)(d) of Listing Regulations.

Kindly take this information on your record.

Thanking You,

Yours Faithfully

For **ANG Lifesciences India Limited**

Rajesh Gupta  
(DIN: 01423407)  
Managing Director



**Factory:**  
Village: Kishanpura,  
Nalagarh Road,  
Tehsil: Baddi,  
Distt.: Solan,  
HP-174101

Regd. Office : SCO-113,  
DARBARA COMPLEX,  
First Floor, B-BLOCK,  
Ranjit Avenue, Amritsar.  
Ph. 0183-5133455, 5133458  
E mail :- operations@anglifesciences.com  
website : www.anglifesciences.com

ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

**AUDITED STANDALONE FINANCIAL RESULTS FOR HALF YEAR ENDED AND THE YEAR ENDED 31st MARCH, 2021**

(In Lacs)

Particulars	Half Year Ended			For the year ended	Previous Year Ended
	31.03.2021	30.09.2020	31.03.2020	31.03.2021	31.03.2020
	Audited	Unaudited	Audited	Audited	Audited
I. Revenue from operations	6825.141	8612.755	6820.130	15437.896	12683.117
II. Other income	12.749	42.838	29.400	55.587	41.974
III. Total Revenue (I + II)	6837.890	8655.593	6849.530	15493.483	12725.091
IV. Expenses:					
(a) Cost of materials consumed	4854.589	5971.341	4683.610	10825.930	8955.675
(b) Changes in Inventories	-566.534	136.657	-115.670	-429.877	-58.770
(c) Employee benefits expense	763.677	603.887	525.930	1367.564	793.631
(d) Finance costs	154.319	142.250	137.880	296.569	286.740
(e) Depreciation and amortization expense	75.335	56.348	68.040	131.683	122.872
(f) Other expenses	1277.390	1010.317	1105.750	2287.707	1784.319
Total expenses	6558.775	7920.800	6405.540	14479.575	11884.468
V. Profit before exceptional and extraordinary items and tax (III-IV)	279.115	734.793	443.990	1013.908	840.623
VI. Exceptional items	0.000	0.000	0.000	0.000	0.000
VII. Profit before extraordinary items and tax (V - VI)	279.115	734.793	443.990	1013.908	840.623
VIII. Extraordinary Items	0.000	0.000	0.000	0.000	0.000
IX. Profit before tax (VII- VIII)	279.115	734.793	443.990	1013.908	840.623
X Tax expense:	0.000				
(1) Current tax	132.900	185.100	127.650	318.000	240.000
(2) Deferred tax	-6.330	-0.525	-8.820	-6.855	-8.939
(3) Mat Credit Entitlement	0.000	0.000	0.000	0.000	0.000
XI Profit (Loss) for the period from continuing operations (VII-VIII)	152.545	550.218	325.160	702.763	609.561
XII Profit/(loss) from discontinuing operations	0.000	0.000	0.000	0.000	0.000
XIII Tax expense of discontinuing operations	0.000	0.000	0.000	0.000	0.000
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.000	0.000	0.000	0.000	0.000



XV	Profit (Loss) for the period (XI + XIV)	152.545	550.218	325.160	702.763	609.561
XVI	Earnings per equity share:					
	(a) Basic & Diluted (Rs.)	2.94	10.62	6.27	13.56	11.76
	(b) Diluted (Rs.)	2.94	10.62	6.27	13.56	11.76

**Notes :**

- 1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on June 30, 2021.
- 2) As the Company's business activities falls with in a single segment, the disclosure requirement of the Accounting Standard AS(17) "Segment Reporting" as notified under Section 133 of the Companies Act, 2013 read with Rule7 of the Companies (Accounts) Rules 2014 are not applicable.
- 3) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to confirm the figures in the current period.
- 4) The Figures for the half year ended 31st March 2021 and corresponding half year i.e. half year ended 31.03.2020 are the balancing figures between the audited figures in respect of the full financial year.
- 5)As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred in ChapterXB of SEBI(Issue of Capital Disclosure requirements) regulations 2009 are exempted from the compulsory requirements of adoption of IND-AS. As the company is covered under the exempted category, the company has not adopted IND -AS for preparation of Financials Results.
- 6) There were no Investors complaints pending as on 31.03.2021.

For ANG Life Sciences India Limited

(Managing Director)  
Rajesh Gupta  
(DIN : 01423407)



Date : 30.06.2021

Place : Amritsar


ANG Life Sciences India Ltd.  
 CIN : L24230PB2006PLC030341  
 Registered Office : 113, First Floor, Darbara Complex,  
 Ranjit Avenue, Amritsar  
 Email ID : cs@anglifesciences.com  
 Website : www.anglifesciences.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Amount in Lacs)

Sr. No.	Particulars	For the year ended	For the year ended
		31.03.2021	31.03.2020
I.	<b>EQUITY AND LIABILITIES</b>		
1	<b>Shareholders' funds</b>		
	(a) <u>Share capital</u>	518.33	518.33
	(b) <u>Reserves and surplus</u>	3639.98	2937.22
	<b>Sub-total-Shareholders' Fund</b>	<b>4158.31</b>	<b>3455.55</b>
2	<b>Non-current liabilities</b>		
	(a) <u>Long-term borrowings</u>	702.93	525.00
	(b) <u>Other Long-term liabilities</u>	278.57	286.21
	(c) <u>Deferred Tax Liabilities (Net)</u>	23.90	30.76
	(d) <u>Long-term Provisions</u>	45.26	20.31
	<b>Sub-total-non Current Liabilities</b>	<b>1050.66</b>	<b>862.27</b>
3	<b>Current liabilities</b>		
	(a) <u>Short Term Borrowings</u>	3293.87	1291.94
	(b) <u>Trade Payables</u>		
	<u>Due to Micro, Small &amp; Medium Enterprise</u>	885.54	443.06
	<u>Due to Others</u>	3118.49	2135.90
	(c) <u>Other current liabilities</u>	1353.54	973.71
	(d) <u>Short-term provisions</u>	504.70	245.08
	<b>Sub-total-Current Liabilities</b>	<b>9156.13</b>	<b>5089.69</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>14365.09</b>	<b>9407.51</b>
II.	<b>ASSETS</b>		
	<b>Non-current assets</b>		
1	(a) <u>Property, Plant and Equipment</u>		
	(i) <u>Tangible assets</u>	2386.49	2093.73
	(ii) <u>Intangible assets</u>	23.12	23.12
	(b) <u>Other non-current Investments</u>	352.00	2.00
	(c) <u>Deferred Tax Assets (Net)</u>	0.00	0.00
	(d) <u>Long-term loans and advances</u>	0.00	0.00
	(e) <u>Other non-current assets</u>	16.57	21.49
	<b>Sub-total-non Current Assets</b>	<b>2778.18</b>	<b>2140.34</b>
2	<b>Current assets</b>		
	(a) <u>Current Investments</u>	0.00	0.00
	(b) <u>Inventories</u>	1925.87	1000.43
	(c) <u>Trade receivables</u>	5874.33	4606.42
	(d) <u>Cash and cash equivalents</u>	386.30	360.05
	(e) <u>Short-term loans and advances</u>	2321.68	725.14
	(f) <u>Other Current Assets</u>	1078.74	575.13
	<b>Sub-total-Current Assets</b>	<b>11586.91</b>	<b>7267.17</b>
	<b>TOTAL ASSETS</b>	<b>14365.09</b>	<b>9407.51</b>
	See accompanying notes forming part of the financial statements.		

For ANG Life Sciences India Limited



(Managing Director)  
 Rajesh Gupta  
 (DIN : 01423407)

Date : 30.06.2021

Place : Amritsar

ANG Life Sciences India Ltd.  
R.O. 113, First Floor, Darbara Complex,  
Ranjit Avenue, Amritsar

(In Lacs)

CASH FLOW STATEMENT FOR THE PERIOD ENDED 31ST MARCH, 2021

Particulars	Year ended 31st March, 2021	Year ended 31st March 2020
(A) CASH FLOW FROM OPERATING ACTIVITIES		
1 Net Profit/(loss) before extraordinary items and Tax	702.76	609.56
2 Adjustments for ;		
a) Depreciation and Amortisation	131.68	122.87
b) Finance Cost Expenses	296.57	286.74
c) Current Taxes	318.00	240.00
d) Deferred Taxes	-6.86	-8.94
e) Preliminary Expenses	0.00	0.00
f) MAT Credit	0.00	0.00
Operating Profit before working capital Changes (1+2)	1442.16	1250.23
3 Adjustments for Working Capital Changes ;		
(i) (Increase)/decrease Operating Assets		
a) Trade Receivables	-1267.92	-431.55
b) Short Term Loans and Advances	-1596.54	-526.16
c) Other Current Assets	-503.61	-48.08
	0.00	0.00
	0.00	0.00
(ii) Increase/(Decrease) in Operating Liabilities	0.00	0.00
a) Trade Payables	1425.06	397.50
b) Short Term Provisions	264.70	20.00
c) Other Current Liabilities	374.74	381.27
d) Other Long Term Liability	-7.64	-3.87
e) Long Term Provisions	24.95	5.25
f) Short Term Borrowings	2001.93	50.49
	0.00	0.00
(iii) (Increase)/Decrease in inventories	-925.44	-346.70
	1232.40	748.39
Less : Income Tax Paid (Net)	-318.00	-265.32
Net Cash from Operating Activities (A)	914.40	483.07
(B) CASH FLOW FROM INVESTING ACTIVITIES		
a) Purchase of Fixed Assets including Capital W.I.P.	-424.44	-164.21
b) Change in Non-Current Assets	4.92	-1.45
c) Change in Non-Current Investment		0.00
Net Cash from Investing Activities (B)	-419.52	-165.66
(C) CASH FLOW FROM FINANCING ACTIVITIES		
a) Interest paid	-296.57	-286.74
b) Proceeds from Long Term Borrowings	395.52	172.50
c) Repayment of Long Term Borrowings	-217.59	-275.27
d) Proceeds from issue of Share Capital	0.00	0.00
e) Proceeds from Share Premium	0.00	0.00
f) Proceeds from sale of assets	0.00	0.00
g) Decrease in Capital Reserve	0.00	-5.00
Net Cash from Financing Activities (C)	-118.64	-394.51
(D) Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	26.24	-77.09
(E) Cash & Cash Equivalents at the beginning of the year	360.05	437.15
(F) Cash & Cash Equivalents at the end of the year	386.30	360.05

Note : 1 Components of Cash & Cash Equivalents

Cash in hand  
Balance with Schedule Banks  
in Current Accounts

2. The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Accounting Standard-3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India


3. The previous year's figures have been regrouped wherever necessary.

For ANG Life Sciences India Limited

(Managing Director)  
Rajesh Gupta  
(DIN : 01423407)

Date : 30.06.2021  
Place : Amritsar





# Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.  
E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated. ....

Independent Auditor's Report on Half Yearly Standalone Financial Results and Standalone Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO  
THE BOARD OF DIRECTORS  
OF ANG LIFESCIENCES INDIA LIMITED

Report on the audit of the Standalone Financial Results

## Opinion

We have audited the accompanying standalone Half yearly financial results of ANG Lifesciences India Limited (the company) for the half year ended 31<sup>st</sup> March, 2021 and the year to date results for the period from 01<sup>st</sup> April, 2020 to 31<sup>st</sup> March, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").


In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the half year ended 31<sup>st</sup> March, 2021 as well as the year to date results for the period from 01<sup>st</sup> April, 2020 to 31<sup>st</sup> March, 2021.

## Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these





# Raman Wadhwa & Co.



**CHARTERED ACCOUNTANT**

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.

E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated. ....

requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Management's Responsibilities for the Standalone Financial Results

These Half Yearly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.





# Raman Wadhwa & Co.



**CHARTERED ACCOUNTANT**

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.

E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated. ....

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



CA. Ishant Sharma  
B.Com, FCA

M: 97805-99974



# Raman Wadhwa & Co.



CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.  
E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated. ....

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Raman Wadhwa & Co.  
Chartered Accountants

Firm Reg. No. 012037N

Ishant Sharma

Partner

M.No. 527055

UDIN: 21527055AAAAER9561

Date: 30.06.2021

Place: Amritsar

CIN No:- L24230PB2006PLC030341  
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/21-22/BSE-10

Date 30/06/2021

To  
Department of Corporate Services,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400001

**Ref: BSE Security Code 540694**

**Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.**

Dear Sir/ Madam,

In accordance with Reg. 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended by SEBI (Listing Obligation and Disclosure Requirements), Regulations 2016, it is hereby declared that M/s Raman Wadhwa & Co., Chartered Accountants, Statutory Auditors of the Company have issued an Auditor's Report with unmodified opinion on the Standalone Audited Financial Results of the Company for the Half year and Financial Year ended March 31, 2021 as approved in the Board Meeting held on 30<sup>th</sup> June, 2021.


Kindly take the same on your record and acknowledge the receipt.

Thanking You,

Yours Faithfully

For **ANG Lifesciences India Limited**

Rajesh Gupta  
(DIN: 01423407)  
Managing Director



**Factory:**  
Village: Kishanpura,  
Nalagarh Road,  
Tehsil: Baddi,  
Distt.: Solan,  
HP-174101

Regd. Office : SCO-113,  
DARBARA COMPLEX,  
First Floor, B-BLOCK,  
Ranjit Avenue, Amritsar.  
Ph. 0183-5133455, 5133458  
E mail :- operations@anglifesciences.com  
website : www.anglifesciences.com